



**INFINITI<sup>®</sup> KRAS-BRAF Assay**  
*Directional Package Insert (DPI)*

**For *In Vitro* Diagnostic Use**



**FOR EXPORT ONLY**

Manufactured by AutoGenomics, Inc., 2980 Scott Street, Vista, CA USA 92081

Authorized EU Agent:      Medical Device Safety Service GmbH (MDSS)  
Schiffgraben 41, 30175 Hannover, Germany

## **INTENDED USE**

The INFINITI KRAS-BRAF Assay is an *in vitro* diagnostic test for the detection and identification of the most prevalent KRAS and BRAF amino acid changes in positions known to affect the function of the proteins. These mutations are identified by detecting their codon variants or nucleotide changes. The INFINITI KRAS-BRAF assay is designed to detect these mutations in formalin-fixed and paraffin-embedded (FFPE) tissue samples.

The INFINITI KRAS-BRAF Assay is a qualitative assay for use in clinical laboratories upon prescription by the attending physician.

## **BACKGROUND INFORMATION**

### ***KRAS***

The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma.

Colorectal cancer - KRAS mutation is predictive of a very poor response to panitumumab (Vectibix®) and cetuximab (Erbix®) therapy in colorectal cancer.<sup>[1]</sup> Currently, the most reliable way to predict whether a colorectal cancer patient will respond to one of the EGFR-inhibiting drugs is to test for certain “activating” mutations in the gene that encodes KRAS, which occur in 40% of colorectal cancers. Studies show patients whose tumors express the mutated version of the KRAS gene will not respond to cetuximab or panitumumab.<sup>[2]</sup>

Lung cancer- Whether a patient is positive or negative for a mutation in the epidermal growth factor receptor (EGFR) will predict how patients will respond to certain EGFR drugs such as Tarceva. EGFR positive patients have an impressive 60% response rate to Tarceva. However, KRAS positivity and EGFR positivity are generally mutually exclusive.<sup>[3][4][5]</sup> Lung cancer patients who are KRAS positive have a low response rate to Tarceva estimated at 5% or less.<sup>[3]</sup>

In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab (Vectibix) and cetuximab (Erbix®)) indicated for treatment of metastatic colorectal cancer to include information about KRAS mutations.<sup>[6]</sup>

### ***BRAF***

BRAF is a human gene that makes a protein called B-Raf. The B-Raf protein is involved in sending signals inside cells, which are involved in directing cell growth. In 2002, it was shown to be faulty (mutated) in human cancers.<sup>[6]</sup>

Acquired mutations in this gene have been found in cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung.<sup>[7]</sup>

More than 30 mutations of the *BRAF* gene associated with human cancers have been identified. The frequency of BRAF mutations varies widely in human cancers from more than 80% in melanomas and nevi, to as little as 0-18% in other tumors, such as 1-3% in lung cancers and 5% in colorectal cancer.<sup>[10]</sup> In 90% of the cases, thymine is substituted with adenine at nucleotide 1799. This leads to valine (V) being substituted for by glutamate (E) at codon 600 (now referred to as V600E) in the activation segment that has been found in human cancers.<sup>[11]</sup> This mutation has been widely observed in papillary thyroid carcinoma, colorectal cancer, melanoma and non-small-cell lung cancer.<sup>[8][9][10][11][12][13][14]</sup>

### TEST PRINCIPLE/ASSAY OVERVIEW

The INFINITI<sup>®</sup> KRAS-BRAF assay is designed to detect the most prevalent KRAS and BRAF amino acid changes in positions known to affect the function of the proteins. These mutations are identified by detecting their codon variants or nucleotide changes.


Gene	Codon	Analyte	Reported mutations detected		
KRAS	12	G12A	Gly12Ala	c.35G>C	GGT>GCT
		G12C	Gly12Cys	c.34G>T	GGT>TGT
		G12D	Gly12Asp	c.35G>A	GGT>GAT
		G12F	Gly12Phe	c.34_35GG>TT	GGT>TTT
		G12R	Gly12Arg	c.34G>C	GGT>CGT
		G12S	Gly12Ser	c.34G>A	GGT>AGT
		G12V	Gly12Val	c.35G>T	GGT>GTT
	13	G13A	Gly13Ala	c.38G>C	GGC>GCC
		G13C	Gly13Cys	c.37G>T	GGC>TGC
		G13D	Gly13Asp	c.38G>A	GGC>GAC
		G13R	Gly13Arg	c.37G>C	GGC>CGC
		G13S	Gly13Ser	c.37G>A	GGC>AGC
		G13V	Gly13Val	c.38G>T	GGC>GTC
	61	Q61E	Gln61Glu	c.181C>G	CAA>GAA
		Q61H1	Gln61His	c.183A>C	CAA>CAC
		Q61H2	Gln61His	c.183A>T	CAA>CAT
		Q61K	Gln61Lys	c.181C>A	CAA>AAA
		Q61L	Gln61Leu	c.182A>T	CAA>CTA
		Q61P	Gln61Pro	c.182A>C	CAA>CCA
		Q61R	Gln61Arg	c.182A>G	CAA>CGA
	BRAE	600	V600A	Val600Ala	c.1799T>C
V600D			Val600Asp	c.1799_1800TG>AT	GTG>GAT
V600E1			Val600Glu	c.1799T>A	GTG>GAG
V600E2			Val600Glu	c.1799_1800TG>AA	GTG>GAA
V600KRM			Val600Lys	c.1798_1799GT>AA	GTG>AAG
			Val600Arg	c.1798_1799GT>AG	GTG>AGG
			Val600Met	c.1798G>A	GTG>ATG

The assay protocol includes the following five major processes:

- Multiplex PCR amplification of DNA.
- Fluorescent label incorporation using analyte specific primer extension (ASPE).
- Hybridization of the ASPE primers to a microarray followed by washing.
- Scanning of the microarray.
- Signal detection and analysis.

Steps (b) through (e) are automated by the CE marked INFINITI Analyzer or INFINITI PLUS Analyzer.

A schematic overview of the assay is shown below.



### DEVICE DESCRIPTION

The INFINITI KRAS-BRAF ASSAY utilizes AutoGenomics' proprietary film-based microarray technology combined with process automation, reagent management and software technology for multiplex detection of the most prevalent KRAS and BRAF amino acid changes in positions known to affect the function of the proteins. These mutations are identified by detecting their codon variants or nucleotide changes.

The INFINITI KRAS-BRAF Assay is comprised of the BioFilmChip<sup>®</sup> Microarray, the Intellipac<sup>®</sup> Reagent Module and the PCR Amplification Mix.

The **BioFilmChip Microarray** consists of a polyester film coated with proprietary multi-layer components designed for DNA analysis. The layers have been designed to provide a versatile surface to enhance test performance. The INFINITI KRAS-BRAF ASSAY uses a microarray chip which has capture probes spotted on the surface of the film. One sample can be run on one microarray. Twelve (12) microarrays are housed in a magazine.

The **Intellipac Reagent Module** which acts as a communication link contains four reservoirs that house the test reagents and has an integrated memory chip. Reagent information such as lot number, expiration date, and volume usage are stored in the memory chip. The Intellipac Reagent Module communicates with the INFINITI Analyzer and provides the reagent information which appears on the assay report and printout. The Intellipac Reagent Management Module provides test reagent for 24 samples.

The **PCR Amplification Mix** consists of the reagents needed for the PCR amplification step of the assay. Each box of the PCR Amplification Mix provides 4 x 250µl vials of PCR Amplification.

The **INFINITI Analyzer and INFINITI PLUS Analyzer** automates the INFINITI KRAS-BRAF ASSAY and integrates all the discrete processes of sample (PCR reaction product) handling, reagent management, hybridization, detection, and results analysis. The assays are processed automatically and read by the built-in confocal microscope. Results are analyzed and presented as positive or negative for the presence of the mutations.

Instructions on how to use the Analyzers are provided in the Operator's Manuals.

The INFINITI Analyzer and INFINITI PLUS Analyzer are CE marked.

## WARNINGS AND PRECAUTIONS

### Handling Requirements

- **For *in vitro* diagnostic use. To be used by qualified laboratory personnel.**
- All patient specimens are potentially hazardous and care should be taken when handling materials of human origin. No test method can offer complete assurance that HCV, HIV or other infectious agents are absent.  
**Follow the CLSI Guidelines (Molecular Diagnostics Methods for Infectious Diseases; Approved Guidelines; MM3-A).**
- Upon receipt of samples, visually inspect sample condition. Specifically, look for abnormal signs that indicate that sample integrity has been compromised (e.g., evaporation, decrease in volume, precipitation, spills, discoloration, sedimentation, separation, turbidity, etc.). If you observe or suspect any sample abnormality, do not perform any test.
- Samples should be handled with extreme caution to prevent contamination, spillage, sample mix-up. Sample containers should be labeled clearly to prevent mix-up.
- Store samples at the specified conditions.
- To minimize the risk of cross contamination, sample preparation, PCR reaction set up and PCR product analysis should be performed according to approved guidelines such as CLSI (Molecular Diagnostic Methods for Genetic Diseases: Approved Guideline).
- Do not pool/mix reagents from different lots.
- Do not use a kit or reagent past its expiration date.
- Store kits and reagents according to the product label.

### Laboratory Procedures

- Follow normal precautions for handling laboratory reagents.
- Follow safe laboratory procedures: do not pipette by mouth; wear protective clothing (e.g., disposable gloves and laboratory coats) and eye protection; do not eat, drink or smoke in the laboratory work areas; wash hands thoroughly after handling samples and reagents.

### Waste Handling

- Dispose of unused reagents, specimens and waste according to applicable country, federal, state and local regulations.
- Material Safety data Sheets (MSDS) are available upon request from AutoGenomics Customer Service.

### Sample Preparation

- Refer to the safety instructions in the package insert provided with the DNA extraction kit used.
- The PCR product cannot be stored prior to loading it onto the microarray. Use immediately.

### INFINITI Analyzer and INFINITI PLUS Analyzer

- **Read the Operator's Manuals before operating the instruments.** Pay particular attention to "Notes".
- Follow the Caution and Safety Warning in the Operator's Manual.
- Refer to the Installation Requirements Section when installing the instrument.
- Refer to the Errors Section when errors are encountered while operating the instrument.
- Refer to the Help Section when problems are encountered.

### STORAGE / STABILITY

BioFilmChip Microarray: 12 months Refrigerated (2 to 8°C)

Intellipac Reagent: 12 months Refrigerated (2 to 8°C)

**Note:** Remove the Intellipac from the Analyzer and store refrigerated as soon as possible. Do not use after Intellipac has been opened for four weeks.

Amplification Mix: 18 months Frozen (-30 to -15°C)

**Note:** Specific product expiration date is printed on the product label.

### MATERIALS PROVIDED (SUFFICIENT FOR 24 TESTS)

- Product Number 02-1110-02 INFINITI KRAS-BRAF BioFilmChip<sup>®</sup> Microarray Magazine
- Product Number 02-2110-02 INFINITI KRAS-BRAF Intellipac<sup>®</sup> Reagent Module  
24 tests per module which contains:
  - 1.1 ml ASPE Master Mix:
    - dNTPs
    - Labeled-dCTP
    - Allele Specific Primers
    - Extension Reaction Buffer
  - 2.6 ml Hybridization Buffer
    - SSC
    - Hybridization Positive Control
    - Sodium Azide Preservative 0.08%
- Product Number 02-3110-02 INFINITI KRAS-BRAF Amplification Mix  
4 x 250µl vials of PCR reaction master mix containing:
  - dNTPs
  - PCR Primer Mix
  - MgCl<sub>2</sub>
  - PCR Reaction Buffer
- **FOR INFINITI Analyzer:** Product Number 12-0010-00: Wash buffer  
*OR*  
**FOR INFINITI PLUS Analyzer:** Product Number 12-0330-00: Buffer Solution BF1

### REAGENTS REQUIRED BUT NOT PROVIDED BY AUTOGENOMICS

- DNA Extraction Kits - The INFINITI KRAS-BRAF Assay can detect the target KRAS and BRAF mutations using genomic DNA, isolated formalin-fixed and paraffin-embedded (FFPE) tissue samples, with sufficient purity, i.e., with the ratio of absorbance at 260 nm to absorbance at 280 nm of  $\geq 1.60$ , and a concentration of 15ng DNA/µl. Any DNA extraction method that meets this specification may be used. The INFINITI KRAS-BRAF Assay has been tested with several commercially available kits. The user can contact AutoGenomics for further information.
- Titanium Taq DNA Polymerase (Clontech, Catalog No: 639209 )
- Exonuclease I (USB, Catalog No: 70073X)
- Shrimp Alkaline Phosphatase (USB, Catalog No: 70092)
- Distilled water (DNase and RNase free)

### EQUIPMENT

The following equipment are required but not provided with the assay reagents

- Pipettors
- Mini Centrifuge
- Pipette tips
- Microfuge tube Racks
- Thermocycler

- Vortex
- 0.2 ml thin wall tubes for PCR
- 1.5 ml microcentrifuge tubes
- 8-well Flat Strip Caps (Genesee Scientific, Catalog No. 22-623)
- AutoGenomics Product Number 11-0060-00: INFINITI Waste tray Stir Bars
- AutoGenomics Product Number 11-0020-00: INFINITI Waste Tray Liners
- AutoGenomics Product Number 11-0080-00: INFINITI Pipette Tips
  
- **FOR INFINITI Analyzer:**
  - AutoGenomics Product Number 10-0010-99: INFINITI Analyzer
  - AutoGenomics Product Number 11-0030-00: 24-Well Plates with Lids
  - AutoGenomics Product Number 11-0050-00: INFINITI Temp Cycle Plate
  
- **FOR INFINITI PLUS Analyzer:**
  - AutoGenomics Product Number 10-0020-99: INFINITI PLUS Analyzer
  - AutoGenomics Product Number 11-0100-00: 48-Well Plates
  - AutoGenomics Product Number 11-0110-00: 48 Well Plate Lid (reusable)

#### **RECOMMENDED DNA CONTROLS**

It is recommended that positive controls be included in each test run. In addition, a negative control (i.e., wild type sample) should also be included in each test run. Cell lines or commercially available DNA with known KRAS-BRAF mutations can be used as positive controls ([www.atcc.org](http://www.atcc.org)). If cell lines are acquired, they will have to be cultured and then the genomic DNA isolated. Please contact technical support at AutoGenomics if additional information is required.

#### **ASSAY PROCEDURE**

##### **DNA Extraction**

Follow the instructions provided with the DNA extraction kit used.

##### **PCR Reaction**

###### **Note:**

- Keep Taq DNA polymerase on ice.
- Completely thaw reagents on ice.
- Vortex the amplification mix tube for 2 to 5 seconds then centrifuge briefly to bring the contents to the bottom of the tube.
- To avoid contamination, a separate area is recommended for assembly of the PCR reaction. Decontaminate pipettes and all work surfaces with freshly prepared 10% bleach in deionized or distilled water.
- Filter tips and gloves must be used when handling specimens and controls.
- The PCR product cannot be stored prior to testing. Use immediately.

###### **Note:**

- For the INFINITI Analyzer use the 24WP.
- For the INFINITI PLUS Analyzer use the 48WP.

1. Thaw Amp mix on ice, centrifuge briefly, vortex 2 to 5 seconds and centrifuge briefly.

- Prepare the PCR master mix.

PCR reaction master mix	17.8 $\mu$ l
<u>Titanium Taq DNA polymerase</u>	<u>0.2 <math>\mu</math>l</u>
Total volume of PCR master mix	18.0 $\mu$ l

**Note:** Calculate the amount of each reagent needed based on the number of reactions.

- Gently vortex the PCR master mix then dispense 18  $\mu$ l of master mix into wells of the well plate.
- Add 2  $\mu$ l of sample DNA to each well.

PCR master mix	18.0 $\mu$ l
<u>Sample DNA</u>	<u>2.0 <math>\mu</math>l</u>
Total volume of amplification reaction	20.0 $\mu$ l

- Place the well plate, sealed with 8-well strip caps, in a thermocycler and immediately commence the amplification reaction using the following program.

Step No.	Temperature $^{\circ}$ C	Time (sec)	No. of Cycles
1	94	120	1
2	94 67 – 57 (-1.0/cycle)	15 15	10
3	94 57	15 15	30
4	94 4	15 Hold	1

**Note:** After each cycle in step 2 the temperature is decreased by 1.0 $^{\circ}$ C. When an Eppendorf Mastercycler EP was used with the ramp rate set at 75%, the total cycling time was 1 hour and 4 minutes ( $\pm$ 5 min). If using other thermocycler models we recommend adjusting the ramp rate in order to obtain an equivalent total cycling time.

#### SAP and Exonuclease I Treatment

Post PCR clean up is a critical step to ensure the remaining substrates would not carry through and interfere with the signal amplification.

- Prepare the enzymes mixture as a master mix. For example, if there are 9 PCR reactions, create a master mix enough for 10 reactions by pipetting 15 $\mu$ l of SAP, 3.75 $\mu$ l of Exonuclease, and 1.25 $\mu$ l of Titanium Taq.

Enzymes mixture (per reaction):

SAP	1.500 $\mu$ l
Exonuclease I	0.375 $\mu$ l
<u>Titanium Taq</u>	<u>0.125 <math>\mu</math>l</u>
Total volume of SAPExo reaction	2.000 $\mu$ l

- Vortex 2 to 5 seconds and centrifuge briefly.



3. Dispense 2 µl of the enzyme mixture per reaction into the completed PCR reaction, seal with 8 well strip caps.
4. Vortex for 1 to 2 seconds and centrifuge briefly.
5. Incubate in thermal cycler using the following conditions.

Step No.	Temperature °C	Time (min)
1	37	60
2	94	20
3	4	Hold

#### Sample Loading

- 1) Carefully remove the 8-well flat strip caps to avoid splashing.
- 2) Load the well plate in the appropriate orientation (with well A1 in the back left corner) into the Analyzer
  - **INFINITI Analyzer:** Load the assembled 24WP with the associated lid (Catalog # 11-0030-00).
  - **INFINITI PLUS Analyzer:** Load the assembled 48WP with a clean 48WP lid (see instructions in the INFINITI PLUS Analyzer Operator's Manual) (Catalog # 11-0110-00, reusable).
- 3) Load the following: assay specific magazines, Intellipac, INFINITI Static Free Pipette tips, and buffer.
  - **FOR INFINITI Analyzer:**  
Wash Buffer should be placed in the INFINITI bottle holders. The Wash Buffer goes in the left holder (near the magazine).
  - **FOR INFINITI PLUS Analyzer:**  
Follow the INFINITI PLUS Analyzer Operator's Manual for checking and replacing Buffer solution BF1.

#### Operation of the Analyzers

Follow the instructions in the Operator's Manuals

**INFINITI Analyzer Operator's Manual (Part Number EM-34000)**

**INFINITI PLUS Analyzer Operator's Manual (Part Number EM-34041)**

#### QUALITY CONTROL

- Maintain calibration of thermocycler according to manufacturer's specifications.
- Maintain calibration of INFINITI or INFINITI PLUS Analyzer according to AutoGenomics' specifications.
- Maintain calibration of pipettes according to manufacturer's specifications.

#### LIMITATIONS

The results obtained from the INFINITI KRAS-BRAF Assay should be used and interpreted only in the context of the overall clinical diagnosis. AutoGenomics is not responsible for any clinical decisions that are taken.

#### INTERPRETATION OF RESULTS

When the integrity of a sample is in question because of suboptimal DNA quantity and/or quality, an amplicon could fail to meet the software's minimum threshold for mutation detection resulting in blanked out calls. In this case, an asterisk shows in the analysis column and the statement: "Calls are not made for

amplicons which do not meet the minimum requirements for mutation detection” is printed at the bottom of the results page. Under these circumstances, a sample may need to be repeated using more (up to 4µl) of DNA in the PCR reaction.

If there are unexpected multiple positives within the same exon from a DNA sample, then chances are insufficient PCR product was made, or assay performance was suboptimal. In this case, the assay should be repeated for that sample.

When the assay is not completed, and no genotype call is made, the assay will need to be repeated. The report displays a message which indicates the reason why no genotype call was made. When an error occurs (e.g., “low DNA”), an Error Log is generated which identifies the problem. Please refer to the Trouble Shooting section of the INFINITI Analyzer Operator’s Manual.

## **PERFORMANCE CHARACTERISTICS**

### ***Analytical Specificity***

Studies related to specificity were conducted during assay development. There are three levels of specificity required in the assay:

- PCR primers
- ASP – target binding region
- ASP – chip binding region

PCR primer specificity was determined by amplicon size on a gel and sequencing the amplicon. ASP primer specificity was determined by the correct calls made by the assay using known samples (e.g., Coriell). Capture probe specificity is determined by hybridizing different oligos and demonstrating that only the correct oligo hybridizes to the known spot.

### ***Limit of Detection (LoD)***

A limit of detection study was conducted to demonstrate the optimal detection range for the INFINITI KRAS-BRAF Assay. Two known DNA samples were diluted to 30ng, 15ng and 5ng. This was equivalent to 60, 30 and 10ng per test. The target/recommended DNA input is 30ng per test. Eight (8) replicates of each sample dilution were tested.

- The two samples were HTB-26D positive for G13D, and HTB-38D positive for V600E1.
- All 24 tests for HTB-26D gave the correct calls.
- All 24 tests for HTB-38D were positive for V600E1, however, three (3) of these samples were also positive for Q61E, and one was positive for G13D and Q61K. This was suspected to be due to incompletely amplified DNA.

The study demonstrated that the optimal detection range for the INFINITI KRAS-BRAF Assay was 10 to 60ng DNA input per test.

### ***Reproducibility***

A study was performed to demonstrate the performance of the assay using different lots of reagents, different instruments and different operators and on different days. The study was performed to demonstrate that the INFINITI KRAS-BRAF reagents can be manufactured that consistently meet the assay specifications and give the correct genotype calls.

The reproducibility data represented six (6) Intellipac reagent lots, five (5) lots of AMP Mix, six (6) lots of microarray chips and four (4) INFINITI Analyzers. The tests were run by three (3) operators and on different days. The same two known DNA samples were tested: one positive for G13D and one positive for V600E1.

The data demonstrated that the INFINITI KRAS-BRAF Assay reagents can be manufactured which consistently meet the specifications of the assay. Except for one test, all tests gave the correct calls. The one failed test had a high background error which was a suspect instrument problem. The raw signal (RFU) data for this test indicated a correct call.

#### ***Sample Carry-over***

Sample carryover studies were performed using ATCC cell lines and a Coriell DNA sample. HTB-26D (positive for G13D), HTB-38D (positive for V600E1), and NA 17017 (wild type sample) were run alternatively at different concentrations to determine if one sample will carry over to next. Results of the studies indicated no sample carry-over contamination.

#### ***Potential Interference from Drugs/Chemicals***

KRAS-BRAF assays that are commercially available use the same specimens and extraction methods and have demonstrated that the quality of the DNA is not affected by any potential interfering substance.

#### ***Analytical Specificity – Method Comparison***

Clinical validation studies were conducted to validate the INFINITI KRAS-BRAF Assay results by sequencing or by a test method currently in use by the laboratory (comparator method). The following were the requirements for the clinical studies:

- Specimens: formalin-fixed and paraffin-embedded (FFPE) tissue samples
- Extraction method: QIAmp DNA Kit
- Concentration of extracted DNA: 15ng/μl
- Acceptance criteria: ≥ 90% concordance with comparator methods

Clinical validation studies for the KRAS mutation detection comprised of a review of two published (peer-reviewed) studies and actual clinical data from clinical laboratories. Overall, the INFINITI KRAS-BRAF Assay made detected 96.6% (201/208) correct KRAS calls and 1.4% (3/208) incorrect KRAS calls compared to the comparator methods, and had 1.4% (3/208) no calls. One (0.5%) INFINITI call was unclear.

Clinical validation study for the BRAF mutation detection was done using actual clinical data. The INFINITI KRAS-BRAF Assay detected 93.5% (43/46) correct calls and 2.2% (1/46) incorrect calls compared to the comparator method, and had 4.3% (2/46) incorrect calls.

## **REFERENCES**

Wikipedia KRAS web page April 24, 2012

Wikipedia BRAF web page April 24, 2012

1. Lièvre A, Bachet JB, Le Corre D, *et al.* (2006). "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer". *Cancer Res.* 66 (8): 3992–5.
2. L. van Epps, PhD, Heather (Winter, 2008). "Bittersweet Gene: A gene called KRAS can predict which colorectal cancers will respond to a certain type of treatment—and which will not.". CURE (Cancer Updates, Research and Education).
3. <sup>a</sup> <sup>b</sup> Suda K, Tomizawa K, Mitsudomi T (March 2010). "Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation". *Cancer Metastasis Rev.* 29 (1): 49–60.

4. Riely GJ, Marks J, Pao W (April 2009). "KRAS mutations in non-small cell lung cancer". *Proc Am Thorac Soc* 6 (2): 201–5.
5. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (January 2005). "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib". *PLoS Med.* 2 (1): e17.
6. OncoGenetics.Org (July 2009). "FDA updates Vectibix and Erbitux labels with KRAS testing info". OncoGenetics.Org. <http://www.oncogenetics.org/web/fda-updates-vectibix-and-erbitux-labels-with-kras-testing-info>.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (June 2002). "Mutations of the BRAF gene in human cancer". *Nature* 417 (6892): 949–54.
8. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006). "BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status". *Mol. Cancer* 5 (1): 2.
9. Benlloch S, Payá A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI, Massutí B (November 2006). "Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology". *J Mol Diagn* 8 (5): 540–3.
10. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH, Kim YS (January 2004). "BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer". *Clin. Cancer Res.* 10 (1 Pt 1): 191–5.
11. Gear H, Williams H, Kemp EG, Roberts F (August 2004). "BRAF mutations in conjunctival melanoma". *Invest. Ophthalmol. Vis. Sci.* 45 (8): 2484–8.
12. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (December 2003). "Determinants of BRAF mutations in primary melanomas". *J. Natl. Cancer Inst.* 95 (24): 1878–90.
13. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusano F (May 2004). "BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas". *J. Clin. Endocrinol. Metab.* 89 (5): 2414–20.
14. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (October 2008). "BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study". *J. Clin. Endocrinol. Metab.* 93 (10): 3943–9.